Stockscreener 앱 받기
0.7525
18.60%
-0.1719
시간 외 거래:
.74
-0.0125
-1.66%
Hcw Biologics Inc 주식(HCWB)의 최신 뉴스
HCW Biologics receives $7M upfront fee from China licensee By Investing.com - Investing.com South Africa
HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 - Minichart
HCW Biologics Secures $7M License Deal for HCW11-006 - TipRanks
HCW Biologics Closes Exclusive Global License for HCW11-006, Receives Upfront Payment - TradingView
[8-K] HCW Biologics Inc. Reports Material Event | HCWB SEC FilingForm 8-K - Stock Titan
HCW Biologics Inc. Receives $7 Million Upfront License Fee from Beijing Trimmune Biotech for HCW11-006 Development and Commercialization Rights - Quiver Quantitative
Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic - TradingView
New fusion immunotherapy deal brings HCW Biologics $7M upfront - Stock Titan
HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN
HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume - Meyka
HCW Biologics highlights positive findings for CAR-T therapy manufacturing - MSN
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - Investing News Network
Small Cap Stocks To Keep An Eye OnMarch 16th - MarketBeat
HCW Biologics Inc. (HCWB) Stock: Science Advances Study Highlights Next-Gen CAR-T Manufacturing Strategy - parameter.io
Trading Volume Surges in Biotech, Tech, and Energy Stocks | Market RecapNews and Statistics - IndexBox
HCW Biologics (HCWB) spikes 71% as micro-cap volatility returns after Nasdaq compliance and recent financing - Quiver Quantitative
HCW Biologics announces positive research results for CAR-T cell therapy - TipRanks
HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy - Asianet Newsable
HCW Biologics’ compound shows promise in CAR-T cell production - Investing.com
HCW Biologics Announces Positive Research Results for CAR-T - GlobeNewswire
Dow Jumps Over 500 Points; NY Empire State Manufacturing Index Falls In March - Sahm
HCW Biologics (NASDAQ: HCWB) seeks approval for large warrant issuances and deep repricing - Stock Titan
HCW Biologics restructures obligations to regain Nasdaq compliance - MSN
Hedge Fund Moves: What is HCW Biologics Incs revenue forecastLayoff News & Low Risk Entry Point Tips - baoquankhu1.vn
AI Stocks: Will HCW Biologics Inc outperform tech stocksTrade Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
Buyout Rumor: Can HCW Biologics Inc stock double in the next yearWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
AI Stocks: Is HCW Biologics Inc forming a breakout patternWeekly Gains Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
HCWB Earnings History & Surprises | EPS & Revenue Results | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics (NASDAQ: HCWB) seeks warrant approvals at Apr 27 meeting - Stock Titan
HCWB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight - The Globe and Mail
HCW Biologics regains compliance with all continued listing rules for Nasdaq per Nasdaq determination letter - marketscreener.com
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - The Manila Times
HCW Biologics (NASDAQ: HCWB) back in full Nasdaq compliance - Stock Titan
HCW Biologics : February 2026 - marketscreener.com
EV Market: Is HCW Biologics Inc gaining market shareJuly 2025 Sector Moves & Stock Timing and Entry Methods - baoquankhu1.vn
EDGAR Filing Documents for 0000950170-24-127198 - SEC.gov
HCW Biologics Completes Follow-On Offering to Fund Pipeline - The Globe and Mail
HCW Biologics Prices $1.5 Million Follow-On Offering of 2.48M Units at $0.6055 - TradingView
HCW Biologics Prices $1.5 Million Unit Offering - marketscreener.com
HCW Biologics lines up $1.5M, cuts warrant price to $0.6055 - Stock Titan
HCW Biologics Announces Follow-On Offering Pricing - Intellectia AI
HCW Biologics Inc. Announces Pricing of Follow-On Offering to Fund Immunotherapy Development - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - marketscreener.com
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewswire Inc.
Chipmakers Recap: Will HCW Biologics Inc outperform tech stocksJuly 2025 Update & Expert-Curated Trade Recommendations - baoquankhu1.vn
HCWB PE Ratio & Valuation, Is HCWB Overvalued - Intellectia AI
HCW Biologics Licenses TRBC Asset to China JV Trimmune - The Globe and Mail
HCW Biologics enters $7 million licensing deal with China-based Trimmune - Investing.com Nigeria
HCW Biologics and WY Biotech announce closing of first round of financing for newly formed joint venture Trimmune - marketscreener.com
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - Investing News Network
Hcw Biologics And Wy Biotech Announce Closing Of First Round Of Financing For Newly Formed Joint Venture Trimmune - TradingView
Inside HCW Biologics’ $7M deal to test a new cancer drug in China - Stock Titan
Is HCW Biologics Inc. forming a breakout patternJuly 2025 Opening Moves & High Accuracy Swing Entry Alerts - mfd.ru
What is HCW Biologics Inc.’s book value per shareWeekly Investment Recap & Technical Pattern Based Buy Signals - mfd.ru
1.20%
0.06%
자본화:
|
볼륨(24시간):